beplay苹果手机能用吗
高级心肺beplay苹果手机能用吗疗法和移植部的研究部负责监督50多种临床试验方案。我们的计划为您的患者提供研究和尖端疗法，尤其是那些高风险或不符合常规批准的心脏疗法的疗法。我们的目标是向任何走过我们家中受益的患者提供临床试验。我们的研beplay苹果手机能用吗究工作包括主要研究人员主导的研究和与许多不同赞助商的临床合作伙伴关系。目前，我们正在积极地在结构性心脏，心力衰竭，外科LVAD和经皮LVAD领域的临床试验中招募患者，这是我们日常实践的一部分。我们的部门也很荣幸举办VAD Journal，这是一个动态的，多学科的，由同行评审的论坛，用于机械辅助循环和先进的心力衰竭领域的所有亚专业。该杂志可以快速传播公正的临床研究和观察结果。beplay苹果手机能用吗
Our goal is to have a clinical trial for every patient that has exhausted currently approved therapies. For more information please email us atHFResearch@uth.tmc.edu.
Currently, we are enrolling patients in the currentclinical trials：
Structural Heart Disease Clinical Trials
Edwards PASCAL Transcatheter Valve Repair System Pivotal Trial (CLASP II TR)
三尖瓣反流（TR）是一种条件，其中心脏的三尖瓣不会紧密地关闭，这会导致心脏循环一部分在不正确的方向上向后流动。这种情况增加了心脏上的工作量，如果不加以治疗，它可能会增加心力衰竭恶化的风险。三尖瓣有三个传单。设备植入物将被放置以掌握这些传单中的每一个，并将它们聚集在一起以帮助减少阀门的泄漏。Pascal植入物将充当填充物，以帮助减少心脏血液中的异常回流。
For more information:https://www.clinicaltrials.gov/ct2/show/NCT04097145
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT)
The purpose of this trial is to evaluate a new investigational device called the Tendyne™ Mitral Valve System. The Tendyne Mitral Valve System is designed for the treatment of a diseased, damaged or malfunctioning mitral valve. This trial will collect information on how safe and effective this device is to treat a leaking mitral valve as compared to the commercially available (approved by the U.S. Food and Drug Administration (FDA)) MitraClip® System. The MitraClip System consists of a delivery catheter and an implantable Clip that is designed to repair the mitral valve by clipping the two leaflets together. The trial will include patients with moderate to severe or severe mitral valve which are not amenable to treatment with MitraClip as well as patients with symptomatic mitral valve disease due to significant calcium deposition on the mitral valve. These patients will be treated with the Tendyne Mitral Valve System and information will be collected for evaluating the safety and efficacy of this device in these patients.
For more information:https://www.clinicaltrials.gov/ct2/show/NCT03433274
SAPIEN™ M3 System Transcatheter Mitral Valve Replacement via Transseptal Access (ENCIRCLE)
这是一项前瞻性的单臂，多中心和自适应设计研究。这项研究的目的是建立Sapien M3系统在有症状的受试者中的安全性和有效性，至少有3个以上的MR，由于临床，解剖或技术考虑因素，其市售手术或经导管治疗方案被认为不适合。
For more information:https://clinicaltrials.gov/ct2/show/NCT04153292
Small Annuli Randomized to Evolut™ or SAPIEN™ Trial (SMART)
这是一个预期的，多中心，国际，随机控制的，后市场
审判。该试验的目的是生成有关瓣膜安全性和自我膨胀（SE）的性能（SE）与气球 - 张开（BE）经导管主动脉瓣置换（TAVR）的临床证据，并在具有较小的主动脉环和症状性严重的严重天然主动脉症状的受试者中。该试验的主要目的是证明与在后12个月后用Sapien 3/3 Ultra System治疗的受试者相比，Evolut Pro/Pro System的临床非效率和血液动力学优势。受试者将以1：1的方式随机分配，以使用Medtronic SE经导管主动脉瓣（TAV）或Edwards为经导管心脏瓣膜（THV）接收TAVR。
For more information:https://clinicaltrials.gov/ct2/show/NCT04722250
心脏移植的临床试验
Surveillance HeartCare® Outcomes Registry (SHORE)
The purpose of this registry is to observe outcomes of heart transplant recipients who are managed with HeartCare. This is done by collecting information about your heart transplant such as test results, biopsy results, and outcomes, storing that information in a database, and using that information for research. Additional blood will be collected for the purposes of this study. The AlloMap® blood test has been cleared by the US Food and Drug Administration (FDA) and available for use since 2005. AlloMap measures the levels of 20 genes in your blood. Your transplant team uses the AlloMap test score, along with other standard tests, to find out how well your body is accepting your new heart. AlloSure-Heart® is another blood test that assesses the transplanted heart for injury. When injury occurs, a special type of DNA called donor-derived cell-free DNA (dd-cfDNA) is released into your blood. AlloSure-Heart measures the amount of dd-cfDNA in the blood. AlloSure-Heart provides information that can help your primary healthcare provider determine the right treatment for you.
For more information:https://www.clinicaltrials.gov/ct2/show/NCT03695601
Interventional Heart Failure Clinical Trials
Reducing Lung Congestion Symptoms Using the V-Wave Shunt in Advanced Heart Failure (RELIEVE HF)
某些类型的心力衰竭可能导致额外的液体保留，从而导致心脏左侧的压力增加。压力增加导致肺部充血。心力衰竭的常见症状可能是由于额外的液体或充血引起的，包括呼吸急促，疲劳和脚或腿部肿胀。研究分流（V波室间分流）植入了心脏的左右心房（顶部腔室）之间的分隔壁（隔膜）。中心的小开口允许少量血液从左上方的腔室流到心脏的右上室。通过转移或“分流”这种少量的血液，心脏左侧的压力增加减少，这有望减少肺部充血并改善心力衰竭的症状。这些患者将接受V波室内SHUNRT的治疗，并将收集信息以评估这些设备在这些患者中的安全性和功效。
For more information:https://www.clinicaltrials.gov/ct2/show/nct03499236
A Prospective, Multi-Center, Randomized, Controlled, Single Blind Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class III Heart Failure Patients (PROACTIVE HF)
This is a prospective, randomized, controlled, single blind, multicenter clinical trial to evaluate the safety and effectiveness of the Cordella PA Sensor System in NYHA Class III Heart Failure Patients. The Cordella PA Sensor will be implanted in conjunction with a right heart catheterization (RHC) procedure and the device will be introduced via percutaneous venous access to the pulmonary artery.
For more information:https://clinicaltrials.gov/ct2/show/NCT04089059
Hemodynamic-GUIDEd Management of Heart Failure (GUIDE-HF)
The purpose of this research study is to evaluate a heart pressure sensor called the CardioMEMS™ PA Sensor (referred to as “the device”) within the CardioMEMS™ HF System. This small sensor is implanted into the heart on the tip of a catheter and through a vein to measure pulmonary artery pressure. The CardioMEMS™ HF System is approved by the U.S. Food and Drug Administration (FDA) for a select group of patients. The study will help to determine if using the device’s data for other indicators of heart failure may reduce heart failure related hospital-admissions. You may be eligible if you are at risk of having episodes of worsening heart failure.
For more information:https://www.clinicaltrials.gov/ct2/show/NCT03387813
Clinical Study of the BioVentrix Revivent TC™ System for Treatment of Left Ventricular Aneurysms (ALIVE)
A Left Ventricular Aneurysm (LVA) is a large area of the left ventricle of the heart that is damaged and no longer ejects blood efficiently. An LVA may result from complications after a heart attack, physical trauma, cardiac disease, or a congenital heart defect. The Revivent TC System study is being conducted to test an investigational device designed to repair a LVA without the use of a heart-lung machine or opening the chest/heart chamber. The device works by placing a tuck in the heart where there is scar. This shortens the distance across the heart and decreases the tension, or stress, on the working heart muscle.
For more information:https://www.clinicaltrials.gov/ct2/show/NCT02931240
Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure with Reduced Ejection Fraction (ANTHEM HFrEF)
ANTHEM-HFrEF is a multi-center, open-label, randomized controlled clinical trial with an adaptive design. Patients with symptomatic heart failure and reduced left ventricular ejection fraction will be enrolled and randomized 2:1 to receive VITARIA system implantation on the right cervical vagus nerve in addition to stable guideline-directed medical therapy (therapy), or to continue receiving stable guideline-directed medical therapy alone (control arm).
Subjects in the therapy arm will receive continuous, periodic VNS stimulation after surgery is completed, and will undergo visits for VNS up titration over a period of 3 months. Subjects in the control arm will also undergo scheduled visits at a similar frequency as the titration visits that are scheduled for subjects in the therapy arm.
For more information:https://clinicaltrials.gov/ct2/show/NCT03425422
机械循环支持临床试验
Antiplatelet Removal and Hemocompatibility Events with the HeartMate 3 Pump (ARIES)
The HeartMate 3 is a U.S. Food and Drug Administration (FDA) approved mechanical heart pump device that pumps blood when the heart cannot. The HeartMate 3 requires pharmaceuticals to keep blood from clotting (also known as “blood thinners,” anticoagulants, and antiplatelet medications). Two blood thinner pharmaceuticals are currently used with the HeartMate 3: aspirin and warfarin. This study is investigating the efficacy comparison between the combination of aspirin and warfarin, as compared to warfarin alone.
For more information:https://www.clinicaltrials.gov/ct2/show/NCT04069156
主要ST-El卸货和延迟再灌注evation Myocardial Infarction (STEMI-DTU)
The study will evaluate the use of a temporary circulatory assist device (heart pump) to support the heart with pumping blood during treatment of the heart attack. This device is called the Impella® CP system or the Impella CP with SmartAssist System (“study device”). The study device has been approved by the U.S. Food and Drug Administration (FDA) for commercial use in the United States to treat patients with different conditions, and who need assistance pumping blood from the heart to the rest of the body.
For more information:https://www.clinicaltrials.gov/ct2/show/NCT03947619
Pulmonary Clinical Trials
A Study to Test the Efficacy and Safety of Inhaled TD139 in Subjects with Idiopathic Pulmonary Fibrosis (GALACTIC-1)
Galecto Biotech AB has begun a study of an investigational drug (also known as the “study drug”) called TD139 as a possible treatment for idiopathic pulmonary fibrosis (IPF). The main purpose of this study is to learn how well the study drug works and how safe the study drug is compared to the placebo.
For more information:https://www.clinicaltrials.gov/ct2/show/NCT03832946
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension (REBUILD)
This is a Phase 3, randomized, double-blind, placebo-controlled dose escalation and verification clinical study to assess the safety and efficacy of pulsed inhaled nitric oxide (iNO) in subjects at risk for pulmonary hypertension associated with pulmonary fibrosis on long term oxygen therapy. The primary objective in this study is to identify the optimal dose and verify the efficacy of iNO in subjects with pulmonary hypertension and pulmonary fibrosis currently receiving treatment with long term oxygen therapy.
For more information:https://clinicaltrials.gov/ct2/show/nct03267108
Chronic Obstructive Pulmonary Disease Clinical Trial
一项前瞻性，多中心，随机，受控的，关键的试验，旨在验证Hemolung®呼吸辅助系统的安全性和功效，用于COPD患者，急性加重需要通气支持（VENT-AVAID）
这项研究的目的是测试使用称为Hemolubeplay苹果手机能用吗ng呼吸辅助系统（Hemolung）的新医学研究设备的安全性和功效。这项研究将与Hemolung系统与Hemolung系统与标准医疗治疗（慢性阻塞性肺疾病（COPD））由于严重的呼吸困难而被接受医院重症监护病房（ICU）。尚未获得美国食品药品监督管理局批准的设备。
For more information:https://www.clinicaltrials.gov/ct2/show/NCT03255057